Reneo Pharmaceuticals (RPHM) News Today

Nantahala Capital Management LLC purchased a new stake in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 547,804 shares of the company's stock, val

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) major shareholder Braden Michael Leonard bought 29,600 shares of Reneo Pharmaceuticals stock in a transaction on Tuesday, September 24th. The stock was acquired at an average price of $1.41 per share, for a total transaction of $41,736.00. Following the purchase, the insider now owns 3,388,649 shares of the company's stock, valued at $4,777,995.09. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) has been assigned a consensus recommendation of "Reduce" from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and seven have assign

Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) have been given an average rating of "Reduce" by the eight ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and seven have issued a hold rating on the

Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) have been given an average recommendation of "Reduce" by the eight brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have given a hold r

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 3,630,000 shares, an increase of 18.2% from the April 30th total of 3,070,000 shares. Approximately 16.7% of the shares of the stock are sold short. Based on an average daily volume of 265,100 shares, the short-interest ratio is currently 13.7 days.

Highbridge Capital Management LLC acquired a new stake in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,121,704 shares of the company's stock, valued at a

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) major shareholder Braden Michael Leonard purchased 414,281 shares of the company's stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average price of $1.54 per share, for a total transaction of $637,992.74. Following the transaction, the insider now directly owns 2,672,194 shares in the company, valued at $4,115,178.76. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) has been given an average rating of "Reduce" by the eight ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to th

HC Wainwright reiterated a "neutral" rating and issued a $1.50 price objective on shares of Reneo Pharmaceuticals in a report on Tuesday.

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) - Analysts at Leerink Partnrs dropped their Q2 2024 EPS estimates for shares of Reneo Pharmaceuticals in a report issued on Tuesday, May 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.22)

BML Capital Management LLC bought a new position in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,314,229 shares of the company's stock, valued at approximately

Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 0.6%